WO2014100022A1 - Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation - Google Patents

Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation Download PDF

Info

Publication number
WO2014100022A1
WO2014100022A1 PCT/US2013/075835 US2013075835W WO2014100022A1 WO 2014100022 A1 WO2014100022 A1 WO 2014100022A1 US 2013075835 W US2013075835 W US 2013075835W WO 2014100022 A1 WO2014100022 A1 WO 2014100022A1
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional
lacto
nutritional composition
lnnt
tetraose
Prior art date
Application number
PCT/US2013/075835
Other languages
English (en)
Inventor
Jomay Chow
Matthew PANASEVICH
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2014100022A1 publication Critical patent/WO2014100022A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the disclosure relates to a nutritional composition for use in enhancing learning and memory in an individual in need thereof. More particularly, the nutritional composition includes at least one human milk oligosaccharide selected from lacto-N- neotetraose, lacto-N-tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'- sialyllactose.
  • LCPUFA long-chain polyunsaturated fatty acids
  • DHA decosahexaenoic acid
  • ARA arachidonic acid
  • the human gut microbiome exists in symbiosis with its host, and it can exert a profound effect on health and disease (Nicholson, 2012). This complex microbial community plays a crucial role in harvesting energy from undigested carbohydrates, promoting maturation of the host immune system, and providing colonization resistance against potential pathogens (Clemente et al., 2012). However, under some conditions, the gut microbiome can also negatively impact human health. Undesirable alterations in the composition of gut microbiota are associated with the development of allergies, Celiac disease, gastric cancer, autism, obesity, anorexia, inflammatory bowel disease (IBD), and type 2 diabetes (Clemente et al., 2012).
  • a nutritional composition for use in enhancing learning and memory in an individual in need thereof comprising at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N- tetraose, 3'-fucosyllactose, and 3'-sialyllactose.
  • retort packaging and “retort sterilizing” are used interchangeably herein, and unless otherwise specified, refer to the common practice of filling a container, most typically a metal can or other similar package, with a nutritional liquid and then subjecting the liquid-filled package to the necessary heat sterilization step, to form a sterilized, retort packaged, nutritional liquid product.
  • the terms "fat” and “oil” as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals. These terms also include synthetic lipid materials so long as such synthetic materials are suitable for oral administration to humans.
  • human milk oligosaccharide or "HMO” as used herein, unless otherwise specified, refers generally to a number of complex carbohydrates found in human breast milk that can be in acidic or neutral form, and to precursors thereof.
  • Exemplary non-limiting human milk oligosaccharides include 3'-sialyllactose (3SL), 6'-sialyllactose (6SL), lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), disialylated lacto-N-tetraose (DSLNT), 3'-fucosyllactose (3FL), and 3'-sialyllactose (3SL), and 2'- fucosyllactose (2FL).
  • 3SL 3'-sialyllactose
  • 6SL 6'-sialyllactose
  • LNnT lacto-N-neotetraose
  • LNT lacto-N-tetraose
  • DSLNT disialylated lacto-N-tetraose
  • 3FL 3'-fucosyllactose
  • 3SL
  • shelf stable refers to a nutritional product that remains commercially stable after being packaged and then stored at 18-24°C for at least 3 months, including from about 6 months to about 24 months, and also including from about 12 months to about 18 months.
  • nutritional formulation or “nutritional composition” as used herein, are used interchangeably and, unless otherwise specified, refer to synthetic formulas including nutritional liquids, nutritional powders, nutritional solids, nutritional semisolids, nutritional semi-liquids, nutritional supplements, and any other nutritional food product as known in the art.
  • the nutritional powders may be reconstituted to form a nutritional liquid, all of which are suitable for oral consumption by a human.
  • the terms “nutritional formulation” or “nutritional composition” do not include human breast milk.
  • nutritional liquid refers to nutritional products in ready-to-drink liquid form, concentrated form, and nutritional liquids made by reconstituting the nutritional powders described herein prior to use.
  • Some semi-solids examples include puddings, gelatins, and doughs.
  • infant or "term infant” as used herein, unless otherwise specified, refers to a person 12 months or younger.
  • preterm infant refers to a person born prior to 36 weeks of gestation.
  • toddler refers to a person greater than one year of age up to three years of age.
  • Child refers to a person greater than three years of age up to twelve years of age.
  • newborn refers to a person from birth up to four weeks of age.
  • infant formula or “synthetic infant formula” as used herein, unless otherwise specified, are used interchangeably and refer to liquid, solid, semi-solid, and semi-liquid human milk replacements or substitutes that are suitable for consumption by an infant.
  • the synthetic formulas include components that are of semi-purified or purified origin.
  • semi-purified or “purified” refer to a material that has been prepared by purification of a natural material or by synthesis.
  • infant formula” or “synthetic infant formula” do not include human breast milk.
  • synthetic pediatric formula refers to liquid, solid, semi-solid, and semi-liquid human milk replacements or substitutes that are suitable for consumption by an infant or toddler up to the age of 36 months (3 years).
  • the synthetic formulas include components that are of semi-purified or purified origin.
  • semi-purified or purified
  • purified refer to a material that has been prepared by purification of a natural material or by synthesis.
  • synthetic pediatric nutritional formula does not include human breast milk.
  • synthetic child formula refers to liquid, solid, semi-solid, and semi-liquid human milk replacements or substitutes that are suitable for consumption by a child up to the age of 12 years.
  • the synthetic formulas include components that are of semi-purified or purified origin.
  • the terms "semi-purified” or “purified” refer to a material that has been prepared by purification of a natural material or by synthesis.
  • “synthetic child nutritional formula” does not include human breast milk.
  • preterm infant formula refers to liquid and solid nutritional products suitable for consumption by a preterm infant.
  • human milk fortifier refers to liquid and solid nutritional products suitable for mixing with breast milk or preterm infant formula or infant formula for consumption by a preterm or term infant.
  • the nutritional compositions as described herein can be administered to individuals including infants as well as pregnant or lactating mothers of such infants or may, in some embodiments, be administered to a specific subclass of infants that are "in need thereof;” that is, to specific infants (or pregnant or lactating mothers of such infants) that would specifically benefit by administration of the infant formula.
  • a specific infant may be "in need of the infant formulas as described herein if they are susceptible to (i.e., genetically predisposed, have a family history of, and/or having symptoms suggestive of a neurological disease or condition) abnormal cognitive development, mental disease or defect, cerebral palsy or other brain disorder.
  • infants "in need of the nutritional compositions disclosed herein are preterm infants.
  • Numerical ranges as used herein are intended to include every number and subset of numbers within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
  • GABA ⁇ -Aminobutyric acid
  • agmatine helps to improve learning, study capability, and concentration.
  • GABA is a primary inhibitory neurotransmitter of the central nervous system. It is thought to increase plasma growth hormone concentration and the rate of protein synthesis in the brain, which helps to facilitate brain development.
  • Animal studies indicate that agmatine increases mental concentration by 85% in the synaptic terminals of rats that were subjected to a spatial learning task. This suggests it plays a pivotal role in this type of learning. Both of these compounds can be absorbed from food or endogenously produced by host cells.
  • GABA and agmatine can be produced in the gut of a human with the already present intestinal flora by feeding particular human milk
  • HMO oligosaccharides
  • a nutritional composition for use in enhancing learning and memory in an individual in need thereof comprising at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N- tetraose, 3'-fucosyllactose, and 3'-sialyllactose.
  • the GAB A, agmatine, or both will then improve learning, study capability, concentration, or any combination thereof in an individual.
  • the GAB A, agmatine, or both may not be required to pass through the blood-brain barrier to have the desirable effect.
  • HMOs that may be included individually or in combination in the compositions used in the method of the present disclosure include: lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, or 3'-sialyllactose.
  • the nutritional composition for use in reducing stress in an individual in need thereof comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose and lacto-N-tetraose.
  • the nutritional composition comprises lacto-N-neotetraose.
  • the nutritional composition comprises lacto-N-tetraose.
  • the nutritional composition is a liquid and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'-sialyllactose, in an amount of from about 0.001 mg/mL to about 20 mg/mL, including from about 0.001 mg/mL to about 10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, including from about 0.01 mg/mL to about 20 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, and including from about 0.01 mg/mL to less than 2 mg/mL.
  • human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto
  • the nutritional composition is a liquid and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose and lacto-N- tetraose, in an amount of from about 0.001 mg/mL to about 20 mg/mL, including from about 0.001 mg/mL to about 10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, and including from about 0.01 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to less than 2 mg/mL.
  • human milk oligosaccharide selected from lacto-N-neotetraose and lacto-N- tetraose
  • the nutritional composition is a liquid and comprises lacto-N-tetraose, in an amount of from about 0.001 mg/mL to about 20 mg/mL, including from about 0.001 mg/mL to about 10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, and including from about 0.01 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to less than 2 mg/mL.
  • the nutritional composition is a liquid and comprises lacto-N-neotetraose, in an amount of from about 0.001 mg/mL to about 20 mg/mL, including from about 0.001 mg/mL to about 10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, and including from about 0.01 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to less than 2 mg/mL.
  • the nutritional composition is a powder and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N- tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'-sialyllactose, in an amount of from about 0.0005% to about 5%, including from about 0.01% to about 1%, by weight of the powder.
  • human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N- tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'-sialyllactose
  • the nutritional composition is a powder and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose and lacto-N- tetraose, in an amount of from about 0.0005% to about 5%, such as from about 0.01% to about 1%), by weight of the powder.
  • the nutritional composition is a powder and comprises lacto-N-tetraose, in an amount of from about 0.0005% to about 5%, such as from about 0.01 ) to about 1%), by weight of the powder.
  • the nutritional composition is a powder and comprises lacto-N-neotetraose, in an amount of from about 0.0005% to about 5%, such as from about 0.01%) to about 1%, by weight of the powder.
  • the nutritional composition is a bar and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N- tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'-sialyllactose, in an amount of from about 0.0005% to about 10%>, including from about 0.01% to about 5%, by weight of the bar.
  • human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N- tetraose, disialylated lacto-N-tetraose, 3'-fucosyllactose, and 3'-sialyllactose
  • the nutritional composition is a bar and comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose and lacto-N- tetraose, in an amount of from about 0.0005% to about 10%, such as from about 0.01% to about 5%>, by weight of the bar.
  • the nutritional composition is a bar and comprises lacto-N-tetraose, in an amount of from about 0.0005% to about 10%, such as from about 0.01 ) to about 5%), by weight of the bar.
  • the nutritional composition is a bar and comprises lacto-N-neotetraose, in an amount of from about 0.0005% to about 10%, such as from about 0.01 ) to about 5%, by weight of the bar.
  • HMOs Human Milk Oligosaccharides
  • Human milk oligosaccharides are one of the main components of human breast milk, which contains, on average, 10 grams per liter of neutral oligosaccharides and 1 gram per liter of acidic oligosaccharides.
  • the composition of human milk is one of the main components of human breast milk, which contains, on average, 10 grams per liter of neutral oligosaccharides and 1 gram per liter of acidic oligosaccharides. The composition of human milk
  • oligosaccharides is very complex and more than 200 different oligosaccharide-like structures are known.
  • the HMOs may be included in the nutritional compositions alone, or in some embodiments, in combination with other immune enhancing factors (e.g., long chain polyunsaturated fatty acids, antioxidants, nucleotides, etc.).
  • the HMO or HMOs may be isolated or enriched from milk(s) secreted by mammals including, but not limited to: human, bovine, ovine, porcine, or caprine species.
  • the HMOs may also be produced via microbial fermentation, enzymatic processes, chemical synthesis, or combinations thereof.
  • the nutritional composition may comprise additional HMOs such as: acidic oligosaccharides, neutral oligosaccharides, n- acetylglucosylated oligosaccharides, and HMO precursors.
  • HMOs such as: acidic oligosaccharides, neutral oligosaccharides, n- acetylglucosylated oligosaccharides, and HMO precursors.
  • disialyllacto-N-fucopentaose II monofucosyldisialyllacto-N-tetraose
  • sialyl fucosyl oligosaccharides i.e., 2'-sialyllactose; 2-sialyllactosamine; 3'-sialyllactose; 3'- sialyllactosamine; 6'-sialyllactose; 6'-sialyllactosamine; sialyllacto-N-neotetraose c; monosialyllacto-N-hexaose; disialyllacto-N-hexaose I; monosialyllacto-N-neohexaose I; monosialyllacto-N-neohexaose II; disialyllacto-N-neohex
  • HMOs lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-neohexaose, monofucosyllacto- N-hexaose II, isomeric fucosylated lacto-N-hexaose (1), isomeric fucosylated lacto-N- hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto-N- neohexaose, difucosyl-para-lacto-N-hexaose, difucosyllacto-N-hexaose, lacto-N- neoocataose, para-
  • Particularly suitable nutritional compositions include at least one of the following HMOs or HMO precursors: sialic acid (SA); 3'-sialyllactose (3'SL); 6'-sialyllactose (6'SL); 2'- fucosyllactose (2'FL); 3 '-fucosyllactose (3'FL); lacto-N-tetraose and lacto-N-neotetraose (LNnT), and in particular, combinations of 6'SL and 3'SL; combinations of 3'FL and SA; combinations of 2'FL and 3'FL; combinations of 2'FL, 3'SL, and 6'SL;
  • SA sialic acid
  • 3'SL 3'-sialyllactose
  • 6'SL 6'-sialyllactose
  • 2'FL fucosyllactose
  • 3'FL lacto-N-tetraose and lacto-N-neotetraose
  • Other exemplary combinations include: SA, 3'SL, 6'SL, 3'FL, 2'FL, and LNnT; 3'SL, 6'SL, 3'FL, 2'FL, and LNnT; SA, 6'SL, 3'FL, 2'FL, and LNnT; SA, 3'SL, 3'FL, 2'FL, and LNnT; SA, 3'SL, 6'SL, 2'FL, and LNnT; SA, 3'SL, 6'SL, 3'FL, and LNnT; SA, 3'SL, 6'SL, 3'FL, and 2'FL; SA and 3'SL; SA and 6'SL; SA and 2'FL; SA and LNnT; SA, 3'SL, and 6'SL; SA, 3'SL and 6'SL; SA, 3'SL and 3'FL; SA, 3'SL and 2'FL; SA, 3'SL and LNnT; SA, 6'SL and 6'SL; SA, 3'SL and 3'FL; SA, 3'SL and
  • the nutritional composition may include LCPUFAs.
  • LCPUFAs are included in the nutritional compositions to provide nutritional support, as well as to reduce oxidative stress and enhance growth and functional development of the intestinal epithelium and associated immune cell populations.
  • the nutritional composition includes a combination of one or more HMOs and one or more LCPUFAs such that the composition provides a synergistic benefit to the end user, such as a synergistic benefit in modulating anti-viral immune responses and dampening inflammation.
  • the HMO or HMOs used in combination with the LCPUFAs to provide the synergistic effect are acidic HMOs.
  • Exemplary LCPUFAs for use in the nutritional compositions include, for example, ⁇ -3 LCPUFAs and ⁇ -6 LCPUFAs. Specific LCPUFAs include
  • docosahexaenoic acid DHA
  • EPA eicosapentaenoic acid
  • DP A docosapentaenoic acid
  • arachidonic acid ARA
  • linoleic acid linolenic acid (alpha linolenic acid)
  • gamma-linolenic acid derived from oil sources such as plant oils, marine plankton, fungal oils, and fish oils.
  • the LCPUFAs are derived from fish oils such as menhaden, salmon, anchovy, cod, halibut, tuna, or herring oil.
  • Particularly preferred LCPUFAs for use in the nutritional compositions with the HMOs include DHA, ARA, EPA, DP A, and combinations thereof.
  • the content of LCPUFAs preferably does not exceed 3% by weight of the total fat content, including below 2% by weight of the total fat content, and including below 1% by weight of the total fat content in the nutritional composition.
  • the LCPUFA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, in esterfied form or as a mixture of one or more of the above, preferably in triglyceride form.
  • the nutritional compositions may comprise total concentrations of LCPUFA of from about 0.01 mM to about 10 mM and including from about 0.01 mM to about 1 mM. Alternatively, the nutritional compositions may comprise total concentrations of
  • LCPUFA of from about 0.001 g/L to about 1 g/L.
  • the nutritional compositions include total long chain ⁇ -6 fatty acids in a concentration of from about 100 to about 425 mg/L or from about 12 to about 53 mg per 100 kcals and/or further include total long chain ⁇ -3 fatty acids in a concentration of from about 40 to about 185 mg/L or from about 5 to about 23 mg per 100 kcals.
  • the ratio of long chain ⁇ -6 fatty acids to long chain ⁇ -3 fatty acids in the nutritional compositions ranges from about 2:1 to about 3: 1, preferably about 2.5: 1.
  • the nutritional compositions include DHA in a concentration of from about 0.025 mg/mL to about 0.130 mg/mL or from about 3 to about 16 mg per 100 kcals.
  • the nutritional compositions include ARA in a concentration of from about 0.080 mg/mL to about 0.250 mg/mL or from about 10 to about 31 mg per 100 kcals.
  • the nutritional compositions include DHA in a concentration of from about 0.025 mg/mL to about 0.130 mg/mL or from about 3 to about 16 mg per 100 kcals.
  • the nutritional compositions include ARA in a concentration of from about 0.080 mg/mL to about 0.250 mg/mL or from about 10 to about 31 mg per 100 kcals.
  • the nutritional compositions include DHA in a concentration of from about 0.025 mg/mL to about 0.130 mg/mL or from about 3 to about 16 mg per 100 kcals.
  • the nutritional compositions include ARA in a concentration of from about 0.080 mg/mL to about 0.
  • compositions include combinations of DHA and ARA such that the ratio of DHA to ARA ranges from about 1 :4 to about 1 :2.
  • the nutritional compositions may comprise one or more antioxidants in combination with the HMOs (and optionally LCPUFAs and/or nucleotides also) to provide nutritional support, as well as to reduce oxidative stress.
  • the nutritional composition includes a combination of HMOs and antioxidants such that the composition provides a synergistic benefit to the end user, such as a synergistic benefit in modulating anti-viral immune responses and dampening inflammation.
  • the HMO or HMOs is used in combination with carotenoids (and specifically lutein, beta-carotene, zeaxanthin and/or lycopene) to provide the synergistic effect.
  • Any antioxidants suitable for oral administration may be included for use in the nutritional compositions of the present disclosure, including, for example, vitamin A, vitamin E, vitamin C, retinol, tocopherol, and carotenoids, including lutein, beta- carotene, zeaxanthin, and lycopene, and combinations thereof, for example.
  • the antioxidants for use in the nutritional compositions may be used with the HMOs alone or in combination with HMOs and LCPUFAs and/or nucleotides.
  • the antioxidants for use in the nutritional compositions include carotenoids.
  • the carotenoids are lutein, lycopene, zeaxanthin and/or beta-carotene.
  • Nutritional compositions containing these combinations, as selected and defined herein, can be used to modulate inflammation and/or levels of C-reactive protein in preterm and term infants.
  • the nutritional compositions may comprise at least one of lutein, lycopene, zeaxanthin, and beta-carotene to provide a total amount of carotenoid of from about 0.001 ⁇ g/mL to about 10 ⁇ g/mL.
  • the nutritional compositions may comprise lutein in an amount of from about 0.001 ⁇ g/mL to about 10 ⁇ g/mL, including from about 0.044 ⁇ g/mL to about 5 ⁇ g/mL of lutein, and from about 0.001 ⁇ g/mL to about 5 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.0190 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.0140 ⁇ g/mL.
  • the nutritional compositions comprise from about 0.001 ⁇ g/mL to about 10 ⁇ g/mL, including from about 0.0185 ⁇ g/mL to about 5 ⁇ g/mL of lycopene and from about 0.001 ⁇ g/mL to about 5 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.0130 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.0075 ⁇ g/mL.
  • the nutritional compositions comprise from about 1 ⁇ g/mL to about 10 ⁇ g/mL, including from about 0.034 ⁇ g/mL to about 5 ⁇ g/mL of beta-carotene and from about 1 ⁇ g/mL to about 5 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.025 ⁇ g/mL, including from about 0.001 ⁇ g/mL to about 0.011 ⁇ g/mL.
  • Other carotenoids may optionally be included in the nutritional compositions. Any one or all of the carotenoids included in the nutritional compositions may be from a natural source, or artificially synthesized.
  • Each of the carotenoids in the selected combinations can be obtained from any known or otherwise suitable material source for use in nutritional compositions, and each can be provided individually, or all together, or in any combination and from any number of sources, including sources such as multivitamin premixes containing other vitamins or minerals in combination with one or more of the carotenoids as described herein.
  • the nutritional compositions may additionally comprise nucleotides and/or nucleotide precursors selected from nucleosides, purine bases, pyrimidine bases, ribose, and deoxyribose.
  • the nucleotide may be in monophosphate, diphosphate, or triphosphate form.
  • the nucleotide may be a ribonucleotide or a deoxyribonucleotide.
  • the nucleotides may be monomeric, dimeric, or polymeric (including RNA and DNA).
  • the nucleotide may be present in the nutritional
  • the nutritional composition as a free acid or in the form of a salt, preferably a monosodium salt.
  • the nutritional composition includes a combination of HMOs and nucleotides such that the composition provides a synergistic benefit to the end user, such as a synergistic benefit in modulating anti-viral immune responses and dampening inflammation and/or improving intestinal barrier integrity.
  • incorporación of nucleotides in the nutritional compositions of the present disclosure improves intestinal barrier integrity and/or maturation, which is beneficial to preterm and term infants who have less developed intestinal flora and hence a slower maturing intestinal barrier.
  • Suitable nucleotides and/or nucleosides for use in the nutritional compositions include one or more of cytidine 5'-monophosphate, uridine 5'-monophosphate, adenosine 5 '-monophosphate, guanosine 5'- 1 -monophosphate, and/or inosine 5 '-monophosphate, such as cytidine 5 '-monophosphate, uridine 5'-monophosphate, adenosine 5'- monophosphate, guanosine 5 '-monophosphate, and inosine 5'-monophosphate.
  • the nucleotides are present in the nutritional compositions in total amounts of nucleotides of at least about 5 mg/L, including at least about 10 mg/L, including from about 10 mg/L to about 200 mg/L, including from about 42 mg/L to about 102 mg/L, and including at least about 72 mg/L of the nutritional product.
  • the nucleotide when the nutritional composition is a nutritional powder, may be present at a level of at least about 0.007%, including from about 0.0078% to about 0.1556%, and including about 0.056% (by weight of the nutritional powder), or at least about 0.007 grams, including from about 0.0078 grams to about 0.1556 grams, and including about 0.056 grams of nucleotide per 100 grams of nutritional powder.
  • the nucleotide when the nutritional composition is a ready-to- feed nutritional liquid, is present at a level of at least about 0.001%, including from about 0.001% to about 0.0197%), and including about 0.0071%) (by weight of the nutritional liquid), or at least about 0.001 grams, including from about 0.001 grams to about 0.0197 grams, and including about 0.0071 grams of nucleotide per 100 grams of ready-to-feed nutritional liquid.
  • the nutritional composition is a
  • the nucleotide is present at a level of at least about 0.0019%, including from about 0.0019% to about 0.0382%, and including about 0.0138% (by weight of the nutritional liquid), or at least about 0.0019 grams, including from about 0.0019 grams to about 0.0382 grams, and including about 0.0138 grams of nucleotide per 100 grams of concentrated nutritional liquid.
  • the nutritional compositions may be formulated to include at least one of protein, fat, and carbohydrate.
  • the nutritional compositions will contain an HMO or HMOs and comprise at least one of fat, protein, and carbohydrate.
  • total concentrations or amounts of the fat, protein, and carbohydrates may vary depending upon the product type (i.e., human milk fortifier, preterm infant formula, infant formula, etc.), product form (i.e., nutritional solid, powder, ready-to-feed liquid, concentrated liquid, or nutritional bar) and targeted dietary needs of the intended user, such concentrations or amounts most typically fall within one of the following embodied ranges, inclusive of any other essential fat, protein, and/or carbohydrate ingredients as described herein.
  • carbohydrate concentrations most typically range from about 5% to about 40%, including from about 7% to about 30%>, including from about 10% to about 25%, by weight; fat concentrations most typically range from about 1% to about 30%), including from about 2% to about 15%, and also including from about 3% to about 10%, by weight; and protein concentrations most typically range from about 0.5% to about 30%), including from about 1% to about 15%, and also including from about 2% to about 10%), by weight.
  • carbohydrate concentrations most typically range from about 10% to about 75%, including from about 10% to about 50%, including from about 20% to about 40%, by weight of the human milk fortifier; fat concentrations most typically range from about 10% to about 40%, including from about 15%) to about 37%), and also including from about 18% to about 30%, by weight of the human milk fortifier; and protein concentrations most typically range from about 5% to about 40%), including from about 10% to about 30%, and also including from about 15% to about 25%, by weight of the human milk fortifier.
  • the amount of carbohydrates, fats, and/or proteins in any of the liquid nutritional compositions described herein may also be characterized in addition to, or in the alternative, as a percentage of total calories in the liquid nutritional composition as set forth in the following tables.
  • These macronutrients for liquid nutritional compositions used in the methods of the present disclosure are most typically formulated within any of the caloric ranges (embodiments A-F) described in the following table (each numerical value is preceded by the term "about").
  • liquid infant formulas both ready-to-feed and concentrated liquids
  • the protein component may comprise from about 7.5% to about 25% of the caloric content of the formula
  • the carbohydrate component may comprise from about 35% to about 50% of the total caloric content of the infant formula
  • the fat component may comprise from about 30% to about 60% of the total caloric content of the infant formula.
  • the protein component is present in an amount of from about 5% to about 35%, including from about 8% to about 12%, and including from about 10% to about 12% by weight of the preterm or term infant formula;
  • the fat component is present in an amount of from about 10% to about 35%, including from about 25%o to about 30%, and including from about 26% to about 28% by weight of the preterm or term infant formula;
  • the carbohydrate component is present in an amount of from about 30% to about 85%, including from about 45% to about 60%, including from about 50% to about 55% by weight of the preterm or term infant formula.
  • the protein component is present in an amount of from about 1% to about 55%, including from about 10% to about 50%, and including from about 10% to about 30% by weight of the human milk fortifier;
  • the fat component is present in an amount of from about 1% to about 30%, including from about 1% to about 25%, and including from about 1% to about 20% by weight of the human milk fortifier;
  • the carbohydrate component is present in an amount of from about 15%) to about 75%), including from about 15% to about 60%, including from about 20% to about 50% by weight of the human milk fortifier.
  • the total amount or concentration of fat, carbohydrate, and protein, in the powdered nutritional compositions used in the methods of the present disclosure can vary considerably depending upon the selected composition and dietary or medical needs of the intended user. Additional suitable examples of macronutrient concentrations are set forth below.
  • the total amount or concentration refers to all fat, carbohydrate, and protein sources in the powdered product.
  • such total amounts or concentrations are most typically and preferably formulated within any of the embodied ranges described in the following table (each numerical value is preceded by the term "about").
  • the protein component is present in an amount of from about 5% to about 45%, including from about 15% to about 35%, and including from about 20% to about 30% by weight of the nutritional bar;
  • the fat component is present in an amount of from about 2% to about 25%, including from about 5%> to about 20%), and including from about 10%> to about 15%> by weight of the nutritional bar;
  • the carbohydrate component is present in an amount of from about 2%> to about 25%o, including from about 5%> to about 20%>, including from about 5%> to about 15% by weight of the nutritional bar.
  • the nutritional compositions used in the methods of the present disclosure may comprise a source or sources of fat.
  • Suitable additional sources of fat for use herein include any fat or fat source that is suitable for use in an oral nutritional product and is compatible with the essential elements and features of such products.
  • the additional fat is derived from long chain polyunsaturated fatty acids and/or short chain fatty acids.
  • suitable fats or sources thereof for use in the nutritional products described herein include coconut oil, fractionated coconut oil, soybean oil, corn oil, olive oil, safflower oil, high oleic safflower oil, oleic acids
  • the nutritional compositions used in the methods of the present disclosure may further comprise protein. Any protein source that is suitable for use in oral nutritional compositions and is compatible with the essential elements and features of such products is suitable for use in the nutritional compositions.
  • Non-limiting examples of suitable proteins or sources thereof for use in the nutritional products include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, which may be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g. , soy) or combinations thereof.
  • suitable proteins or protein sources include milk protein isolates, milk protein concentrates as described herein, casein protein isolates, extensively hydrolyzed casein, whey protein, sodium or calcium casemates, whole cow milk, partially or completely defatted milk, soy protein isolates, soy protein concentrates, and so forth.
  • the nutritional compositions include a protein source derived from milk proteins of human and/or bovine origin.
  • the nutritional products used in the methods of the present disclosure may further optionally comprise any carbohydrates that are suitable for use in an oral nutritional product and are compatible with the essential elements and features of such products.
  • Non-limiting examples of suitable carbohydrates or sources thereof for use in the nutritional products described herein may include maltodextrin, hydrolyzed or modified starch or cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrates, pea-derived carbohydrates, potato-derived carbohydrates, tapioca, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), artificial sweeteners (e.g., sucralose, acesulfame potassium, stevia) and combinations thereof.
  • a particularly desirable carbohydrate is a low dextrose equivalent (DE) maltodextrin.
  • DE dextrose equivalent
  • the nutritional compositions used in the methods of the present disclosure may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population.
  • Such optional ingredients are known or otherwise suitable for use in medical food or other nutritional products or pharmaceutical dosage forms and may also be used in the compositions herein, provided that such optional ingredients are safe for oral
  • Non-limiting examples of such optional ingredients include preservatives, emulsifying agents, buffers, fructooligosaccharides, galactooligosaccharides,
  • polydextrose and other prebiotics (e.g., other neutral or acidic HMOs, inulin,
  • probiotics e.g., B. animalis subsp. lactis BB-12, B. lactis HN019, B. lactis Bi07, L. rhamnosus GG, L. rhamnosus HNOOl, L. acidophilus LA-5, L. acidophilus NCFM, L. fermentum CECT5716, B.
  • antioxidant/anti-inflammatory compounds including tocopherols, caroteinoids, ascorbate/ vitamin C, ascorbyl palmitate, polyphenols (e.g., curcumin), glutathione, and superoxide dismutase (melon), milk protein of human and/or bovine origin, soy protein, pea protein, other bioactive factors (e.g., growth hormones, cytokines, TFG- ⁇ ) of human and/or bovine origin, tributyrin or other SCFA-containing mono-, di-, or triglylcerides, human milk-derived lipids, free amino acids or peptides (e.g., HMB, arginine, leucine, and/or glutamine), lactose, other water- and fat-soluble vitamins, minerals, and trace elements, pharmaceutical actives, additional nutrients as described herein,
  • the nutritional compositions may further comprise a sweetening agent, preferably including at least one sugar alcohol such as maltitol, erythritol, sorbitol, xylitol, mannitol, isomalt, and lactitol, and also preferably including at least one artificial or high potency sweetener such as acesulfame K, aspartame, sucralose, saccharin, stevia, and tagatose.
  • a sweetening agents especially as a combination of a sugar alcohol and an artificial sweetener, are especially useful in formulating liquid beverage embodiments of the present disclosure having a desirable favor profile.
  • These sweetener combinations are especially effective in masking undesirable flavors sometimes associated with the addition of vegetable proteins to a liquid beverage.
  • Optional sugar alcohol preferably including at least one sugar alcohol such as maltitol, erythritol, sorbitol, xylitol, mannitol, isomalt, and lactito
  • concentrations in the nutritional product may range from at least 0.01%, including from about 0.1% to about 10%>, and also including from about 1% to about 6%, by weight of the nutritional product.
  • Optional artificial sweetener concentrations may range from about 0.01%), including from about 0.05%> to about 5%, also including from about 0.1 % to about 1.0%), by weight of the nutritional product.
  • a flowing agent or anti-caking agent may be included in the nutritional compositions as described herein to retard clumping or caking of the powder over time and to make a powder embodiment flow easily from its container.
  • Any known flowing or anti-caking agents that are known or otherwise suitable for use in a nutritional powder or product form are suitable for use herein, non-limiting examples of which include tricalcium phosphate, silicates, and combinations thereof.
  • the concentration of the flowing agent or anti-caking agent in the nutritional composition varies depending upon the product form, the other selected ingredients, the desired flow properties, and so forth, but most typically range from about 0.1% to about 4%, including from about 0.5% to about 2%, by weight of the nutritional composition.
  • a stabilizer may also be included in the nutritional compositions. Any stabilizer that is known or otherwise suitable for use in a nutritional composition is also suitable for use herein, some non-limiting examples of which include gums such as xanthan gum.
  • the stabilizer may represent from about 0.1% to about 5.0%, including from about 0.5% to about 3%, including from about 0.7% to about 1.5%, by weight of the nutritional composition.
  • the nutritional compositions may further comprise any of a variety of other vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin I1 ⁇ 2, carotenoids (e.g., beta-carotene, zeaxanthin, lutein, lycopene), niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof.
  • carotenoids e.g., beta-carotene, zeaxanthin, lutein, lycopene
  • niacin folic acid
  • pantothenic acid biotin
  • vitamin C choline
  • inositol salts and derivatives thereof, and combinations thereof.
  • the nutritional compositions may further comprise any of a variety of other additional minerals, non-limiting examples of which include calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, chloride, and combinations thereof.
  • the nutritional compositions used in the methods of the present disclosure may be prepared by any known or otherwise effective manufacturing technique for preparing the selected product solid or liquid form. Many such techniques are known for any given product form such as nutritional liquids, powders, and nutritional bars, and can easily be applied by one of ordinary skill in the art to the nutritional compositions described herein.
  • the nutritional compositions used in the methods of the present disclosure can therefore be prepared by any of a variety of known or otherwise effective formulation or manufacturing methods.
  • a suitable manufacturing process for example, at least three separate slurries are prepared, including a protein-in-fat (PIF) slurry, a
  • the carbohydrate-mineral (CHO-MIN) slurry is formed by heating and mixing the oil (e.g., canola oil, corn oil, etc.) and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate, etc.) with continued heat and agitation.
  • the CHO-MIN slurry is formed by adding with heated agitation to water: minerals (e.g., potassium citrate, dipotassium phosphate, sodium citrate, etc.), trace and ultra trace minerals (TM/UTM premix), thickening or suspending agents (e.g.
  • CHO-MIN CHO-MIN slurry
  • additional minerals e.g., potassium chloride, magnesium carbonate, potassium iodide, etc.
  • carbohydrates e.g., HMOs, fructooligosaccharide, sucrose, corn syrup, etc.
  • the PIW slurry is then formed by mixing with heat and agitation the remaining protein, if any.
  • the resulting slurries are then blended together with heated agitation and the pH adjusted to 6.6-7.0, after which the composition is subjected to high-temperature short- time (HTST) processing during which the composition is heat treated, emulsified and homogenized, and then allowed to cool.
  • HTST high-temperature short- time
  • Water soluble vitamins and ascorbic acid are added, the pH is adjusted to the desired range if necessary, flavors are added, and water is added to achieve the desired total solid level.
  • the composition is then aseptically packaged to form an aseptically packaged nutritional emulsion. This emulsion can then be further diluted, heat-treated, and packaged to form a ready-to-feed or concentrated liquid, or it can be heat-treated and subsequently processed and packaged as a
  • reconstitutable powder e.g. , spray dried, drymixed, agglomerated.
  • the nutritional solid such as a spray dried nutritional powder or drymixed nutritional powder, may be prepared by any collection of known or otherwise effective technique, suitable for making and formulating a nutritional powder.
  • One method of preparing the spray dried nutritional powder comprises forming and homogenizing an aqueous slurry or liquid comprising predigested fat, and optionally protein, carbohydrate, and other sources of fat, and then spray drying the slurry or liquid to produce a spray dried nutritional powder.
  • the method may further comprise the step of spray drying, drymixing, or otherwise adding additional nutritional ingredients, including any one or more of the ingredients described herein, to the spray dried nutritional powder.
  • the nutritional composition may be in the form of a bar.
  • the safflower oil, lecithin, glycerin, water, and flavors are added to a mixer.
  • the dry powder ingredients and the vitamin mineral premix are added to the mixer and mixed for 1 minute.
  • Corn syrup (heated to 95-105 °F) is added to the mixer and mixed for 2 minutes. Soy crisps and marshmallow bits are added to the mixer and mixed for 2 minutes. Chilled chocolate drops are added to the mixer and mixed for 1 minute.
  • the mixture is formed into bars.
  • a coating preheated to 95-100 °F
  • Many different ingredients and mixing procedures may be used to make a nutritional bar.
  • compositions used in the methods of the present disclosure may be formulated and administered in any known or otherwise suitable oral product form.
  • Any solid, liquid, semi-solid, semi-liquid, or powder product form, including combinations or variations thereof, are suitable for use herein, provided that such forms allow for safe and effective oral delivery to the individual of the ingredients as also defined herein.
  • compositions used in the methods of the present disclosure are desirably formulated as dietary product forms, which are defined herein as those embodiments comprising the ingredients of the present disclosure in a product form that then contains at least one of fat, protein, and carbohydrate, and preferably also contains vitamins, minerals, or combinations thereof.
  • the nutritional compositions may be formulated with sufficient kinds and amounts of nutrients to provide a sole, primary, or supplemental source of nutrition, or to provide a specialized nutritional product for use in individuals afflicted with specific conditions or with a targeted nutritional benefit as described below.
  • Some exemplary, non- limiting, examples of specific products that may be suitable for use in accordance with the present disclosure include preterm infant formulas, term infant formulas, human milk fortifiers, pediatric formulas, adult nutritional formulas, older adult nutritional formulas, medical formulas, geriatric nutritional formulas, diabetic nutritional formulas, nutritional bars, and the like.
  • Nutritional liquids include both concentrated and ready-to-feed nutritional liquids. These nutritional liquids are most typically formulated as suspensions or emulsions, although other liquid forms are within the scope of the present disclosure.
  • Nutritional emulsions suitable for use may be aqueous emulsions comprising proteins, fats, and carbohydrates. These emulsions are generally flowable or drinkable liquids at from about 1°C to about 25°C and are typically in the form of oil-in- water, water-in-oil, or complex aqueous emulsions, although such emulsions are most typically in the form of oil-in- water emulsions having a continuous aqueous phase and a discontinuous oil phase.
  • the nutritional emulsions may be and typically are shelf stable.
  • the nutritional emulsions typically contain up to 95% by weight of water, including from about 50%) to 95%), also including from about 60%> to about 90%>, and also including from about 70% to about 85%, of water by weight of the nutritional emulsions.
  • the nutritional emulsions may have a variety of product densities, but most typically have a density greater than 1.03 g/mL, including greater than 1.04 g/mL, including greater than 1.055 g/mL, including from about 1.06 g/mL to about 1.12 g/mL, and also including from about 1.085 g/mL to about 1.10 g/mL.
  • the nutritional emulsions may have a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the emulsions comprise generally at least 19 kcal/fl oz (660 kcal/liter), more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 25 kcal/fl oz (820 kcal/liter), even more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 24 kcal/fl oz (800-810 kcal/liter).
  • the 22-24 kcal/fl oz formulas are more commonly used in preterm or low birth weight infants, and the 20-21 kcal/fl oz (675-680 to 700 kcal/liter) formulas are more often used in term infants.
  • the emulsion may have a caloric density of from about 50-100 kcal/liter to about 660 kcal/liter, including from about 150 kcal/liter to about 500 kcal/liter. In some specific embodiments, the emulsion may have a caloric density of 25, or 50, or 75, or 100 kcal/liter.
  • the nutritional emulsion may have a pH ranging from about 3.5 to about
  • a typical serving size is generally at least 1 mL, or even at least 2 mL, or even at least 5 mL, or even at least 10 mL, or even at least 25 mL, including ranges from 1 mL to about 300 mL, including from about 4 mL to about 250 mL, and including from about 10 mL to about 240 mL.
  • the nutritional solids may be in any solid form but are typically in the form of flowable or substantially flowable particulate compositions, or at least particulate compositions.
  • Particularly suitable nutritional solid product forms include spray dried, agglomerated and/or dryblended powder compositions. The compositions can easily be scooped and measured with a spoon or similar other device, and can easily be
  • immediate oral or enteral use generally means within about 48 hours, most typically within about 24 hours, preferably right after reconstitution.
  • the nutritional powders may be reconstituted with water prior to use to a caloric density tailored to the nutritional needs of the ultimate user, although in most instances the powders are reconstituted with water to form compositions comprising at least 19 kcal/fl oz (660 kcal/liter), more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 25 kcal/fl oz (820 kcal/liter), even more typically from about 20 kcal/fl oz (675-680 kcal/liter) to about 24 kcal/fl oz (800-810 kcal/liter).
  • the 22-24 kcal/fl oz formulas are more commonly used in preterm or low birth weight infants, and the 20-21 kcal/fl oz (675-680 to 700 kcal/liter) formulas are more often used in term infants.
  • the reconstituted powder may have a caloric density of from about 50-100 kcal/liter to about 660 kcal/liter, including from about 150 kcal/liter to about 500 kcal/liter.
  • the emulsion may have a caloric density of 25, or 50, or 75, or 100 kcal/liter.
  • the exemplified compositions are shelf stable nutritional compositions prepared in accordance with the manufacturing methods described herein, such that each exemplified composition, unless otherwise specified, includes an aseptically processed embodiment and a retort packaged embodiment.
  • Soybean oil 10.6 10.6 10.6 10.6
  • Tricalcium phosphate 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g
  • Soybean oil 10.6 10.6 10.6 10.6
  • Tricalcium phosphate 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g
  • Whey protein concentrate 12.20 12.20 12.20 12.20
  • Tricalcium phosphate AN AN AN AN AN
  • Soybean oil 10.6 10.6 10.6 10.6
  • 6' sialyllactose (6'SL) 0.049 0.097 0.245 0.490 0.98
  • Tricalcium phosphate 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g
  • Lacto-N-neotetraose (LNnT) 0.097 0.194 0.490 0.98 1.96
  • Whey protein concentrate 12.20 12.20 12.20 12.20
  • Tricalcium phosphate AN AN AN AN AN
  • Lacto-N-neotetraose (LNnT) 0.049 0.097 0.245 0.490 1.96
  • Vitamin D3 20.0 g 20.0 g 20.0 g 20.0 g 20.0 g 20.0 g 20.0 g
  • Lacto-N-neotetraose (LNnT) 0.385 0.770 1.925 3.85 30.8
  • Soy lecithin 1.120 1.120 1.120 1.120 1.120
  • Vitamin mineral premix 1.116 1.116 1.116 1.116 1.116
  • Oleic Safflower Oil 32.40 32.40 32.40 32.40 32.40 32.40
  • Soy Lecithin 0.30 0.30 0.30 0.30 0.30 0.30 0.30 0.30 0.30 0.30 0.30 lacto-N-neotetraose (LNnT) 1.00 2.00 5.00 10.00 80.00
  • Acesulfame Potassium 76.0 g 76.0 g 76.0 g 76.0 g 76.0 g dl-Alpha-Tocopheryl Acetate 54.5 g 54.5 g 54.5 g 54.5 g 54.5 g 54.5 g
  • Vitamin D3 13.2 mg 13.2 mg 13.2 mg 13.2 mg 13.2 mg
  • Vitamin A Palmitate 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g
  • Vitamin A palmitate 4.3 g 4.3 g 4.3 g 4.3 g 4.3 g 4.3 g 4.3 g
  • Vitamin D3 13.3 mg 13.3 mg 13.3 mg 13.3 mg 13.3 mg 13.3 mg

Abstract

La présente invention concerne une composition nutritive utilisée afin de favoriser l'apprentissage et la mémorisation chez un individu en ayant besoin, ladite composition nutritive contenant au moins un oligosaccharide du lait humain choisi parmi le lacto-N-néotétraose, le lacto-N-tétraose, le lacto-N-tétraose disialylé, le 3'-fucosyllactose et le 3'-sialyllactose.
PCT/US2013/075835 2012-12-18 2013-12-17 Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation WO2014100022A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738486P 2012-12-18 2012-12-18
US61/738,486 2012-12-18

Publications (1)

Publication Number Publication Date
WO2014100022A1 true WO2014100022A1 (fr) 2014-06-26

Family

ID=49917759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/075835 WO2014100022A1 (fr) 2012-12-18 2013-12-17 Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation

Country Status (2)

Country Link
TW (1) TW201438720A (fr)
WO (1) WO2014100022A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085077A1 (fr) * 2013-12-04 2015-06-11 Abbott Laboratories Procédé visant à l'amélioration de la mémoire et de l'apprentissage par l'administration d'acide sialique
WO2016014473A1 (fr) * 2014-07-21 2016-01-28 Abbott Laboratories Système d'administration de nutriments avec des oligosaccharides de lait humain
WO2016086157A1 (fr) * 2014-11-26 2016-06-02 Abbott Laboratories Préparation pour nourrisson comprenant des olisaccharides de lait humain, des acides gras polyinsaturés, des nucléotides et de la lutéine
WO2017198276A1 (fr) * 2016-05-19 2017-11-23 Glycom A/S Composition synthétique
WO2018215572A1 (fr) * 2017-05-24 2018-11-29 Nestec S.A. Composition contenant des oligosaccharides du lait maternel (hmo), destinée à être utilisée dans l'amélioration de la mémoire à court terme et d'autres avantages cognitifs
WO2019087140A1 (fr) * 2017-11-02 2019-05-09 Glycom A/S Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration
CN110769703A (zh) * 2017-05-24 2020-02-07 雀巢产品有限公司 用于改善短期记忆和其他认知益处的包含低聚果糖(of)的组合物
US10729707B2 (en) 2016-07-28 2020-08-04 Fonterra Co-Operative Group Limited Dairy product and process
CN111683666A (zh) * 2017-12-22 2020-09-18 格礼卡姆股份公司 预防或减少伤害感受的包含hmo的组合物
WO2021115990A1 (fr) 2019-12-09 2021-06-17 Société des Produits Nestlé S.A. Compositions comprenant des oligosaccharides de lait humain destinées à être utilisées chez un sujet pour aider au développement du langage
RU2791622C2 (ru) * 2017-05-24 2023-03-13 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигосахариды грудного молока (огм), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306908B1 (en) 1997-02-21 2001-10-23 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US20030118703A1 (en) 2001-12-12 2003-06-26 Nguyen Minhthy Le Methods and compositions for brightening the color of thermally processed nutritionals
US20090098240A1 (en) 2007-05-17 2009-04-16 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
US20120171165A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US20120172319A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
WO2013025104A1 (fr) * 2011-08-16 2013-02-21 Friesland Brands B.V. Compositions nutritionnelles comprenant des oligosaccharides de lait humain et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306908B1 (en) 1997-02-21 2001-10-23 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6589576B2 (en) 2000-02-04 2003-07-08 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US20030118703A1 (en) 2001-12-12 2003-06-26 Nguyen Minhthy Le Methods and compositions for brightening the color of thermally processed nutritionals
US20090098240A1 (en) 2007-05-17 2009-04-16 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
US20120171165A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US20120172319A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
WO2013025104A1 (fr) * 2011-08-16 2013-02-21 Friesland Brands B.V. Compositions nutritionnelles comprenant des oligosaccharides de lait humain et leurs utilisations

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CLEMENTE JC; URSELL LK; WEGENER PARFREY L ET AL.: "The impact of the gut microbiota on human health: an integrative view", CELL, vol. 148, 2012, pages 1258 - 70
DESBONNET L; GARRETT L; CLARKE G ET AL.: "The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat", J PSYCHIATR RES, vol. 43, 2008, pages 164 - 74
DIAZ HEIJTZ R; WANG S; ANUAR F ET AL.: "Normal gut microbiota modulates brain development and behavior", PNAS, vol. 108, 2011, pages 3047 - 52
DUNCKER SC; KAMIYA T; WANG L ET AL.: "Probiotic Lactobacillus reuteri alleviates the response to gastric distension in rats", J NUTR, vol. 141, 2011, pages 1813 - 18
KAMIYA T; WANG L; FORSYTHE, P ET AL.: "Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats", GUT, vol. 55, 2006, pages 191 - 96
KUNZ C ET AL: "OLIGOSACCHARIDES IN HUMAN MILK: STRUCTURAL, FUNCTIONAL, AND METABOLIC ASPECTS", ANNUAL REVIEW OF NUTRITION, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 20, 1 January 2000 (2000-01-01), pages 699 - 722, XP009020860, ISSN: 0199-9885, DOI: 10.1146/ANNUREV.NUTR.20.1.699 *
MCKERNAN DP; FITZGERALD P; FINAN TG ET AL.: "The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat", NEUROGASTROENTEROL MOTIL, vol. 22, 2010, pages 1029 - 36
NICHOLSON JK: "Host-gut microbiota metabolic interactions", SCIENCE, vol. 336, 2012, pages 1262 - 67
WALL R; MARQUES TM; O'SULLIVAN O ET AL.: "Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota", AM J CLIN NUTR, vol. 95, 2012, pages 1278 - 87

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085077A1 (fr) * 2013-12-04 2015-06-11 Abbott Laboratories Procédé visant à l'amélioration de la mémoire et de l'apprentissage par l'administration d'acide sialique
WO2016014473A1 (fr) * 2014-07-21 2016-01-28 Abbott Laboratories Système d'administration de nutriments avec des oligosaccharides de lait humain
WO2016086157A1 (fr) * 2014-11-26 2016-06-02 Abbott Laboratories Préparation pour nourrisson comprenant des olisaccharides de lait humain, des acides gras polyinsaturés, des nucléotides et de la lutéine
CN106998774A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 包含人乳低聚糖、多不饱和脂肪酸、核苷酸以及叶黄素的婴儿配方
WO2017198276A1 (fr) * 2016-05-19 2017-11-23 Glycom A/S Composition synthétique
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
US10729707B2 (en) 2016-07-28 2020-08-04 Fonterra Co-Operative Group Limited Dairy product and process
CN110799045A (zh) * 2017-05-24 2020-02-14 雀巢产品有限公司 用于改善短期记忆和其他认知益处的包含人乳低聚糖(hmo)的组合物
CN110769703A (zh) * 2017-05-24 2020-02-07 雀巢产品有限公司 用于改善短期记忆和其他认知益处的包含低聚果糖(of)的组合物
US11026444B2 (en) 2017-05-24 2021-06-08 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides (HMO) for use in the improvement of short term memory and other cognitive benefits
WO2018215572A1 (fr) * 2017-05-24 2018-11-29 Nestec S.A. Composition contenant des oligosaccharides du lait maternel (hmo), destinée à être utilisée dans l'amélioration de la mémoire à court terme et d'autres avantages cognitifs
RU2791622C2 (ru) * 2017-05-24 2023-03-13 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигосахариды грудного молока (огм), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ
WO2019087140A1 (fr) * 2017-11-02 2019-05-09 Glycom A/S Un ou plusieurs hmos pour réduire ou prévenir la fatigue et/ou améliorer la focalisation ou la concentration
CN111526879A (zh) * 2017-11-02 2020-08-11 格礼卡姆股份公司 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
US11541069B2 (en) 2017-11-02 2023-01-03 Glycom A/S One or more HMOs for reducing or preventing fatigue and/or improving focus or concentration
CN111683666A (zh) * 2017-12-22 2020-09-18 格礼卡姆股份公司 预防或减少伤害感受的包含hmo的组合物
WO2021115990A1 (fr) 2019-12-09 2021-06-17 Société des Produits Nestlé S.A. Compositions comprenant des oligosaccharides de lait humain destinées à être utilisées chez un sujet pour aider au développement du langage
CN115209745A (zh) * 2019-12-09 2022-10-18 雀巢产品有限公司 用于在个体中使用以支持语言发育的包含人乳低聚糖的组合物

Also Published As

Publication number Publication date
TW201438720A (zh) 2014-10-16

Similar Documents

Publication Publication Date Title
US10779550B2 (en) Human milk oligosaccharides to ameliorate symptoms of stress
US11179406B2 (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11160817B2 (en) Nutritional compositions comprising neuroprotective dietary oligosaccharides
US20220354876A1 (en) Human milk oligosaccharides to promote growth of beneficial bacteria
CA2822660C (fr) Combinaison symbiotique de probiotique et d'oligosaccharides de lait humain
US10639319B2 (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014100022A1 (fr) Oligosaccharides alimentaires destinés à favoriser l'apprentissage et la mémorisation
US20230020348A1 (en) Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014100225A1 (fr) Utilisation nutritionnelle d'oligosaccharides de lait humain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13817816

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13817816

Country of ref document: EP

Kind code of ref document: A1